Disease · MONDO_0005082
prostate adenocarcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. prostate adenocarcinoma. Diseases, record MONDO_0005082. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005082
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- adenocarcinoma of prostate, adenocarcinoma of the prostate, prostate gland adenocarcinoma
- Open Targets
Drugs89
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| BICALUTAMIDE | CHEMBL409 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| FLUTAMIDE | CHEMBL806 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| LEUPROLIDE | CHEMBL1201199 | Protein | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| LEUPROLIDE ACETATE | CHEMBL1200775 | Protein | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| TESTOSTERONE | CHEMBL386630 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 0 | Drugs and targets |
| GOSERELIN | CHEMBL1201247 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| BUSERELIN | CHEMBL2110824 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GOSERELIN ACETATE | CHEMBL1200501 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 89
See all 89 drugsTargets141
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AR | Androgen receptor | 9 | Androgen Receptor agonist; Androgen Receptor antagonist | Phase 3 | https://conductscience.org/library/genes/367 | Drugs and targets |
| GNRHR | Gonadotropin-releasing hormone receptor | 8 | Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2798 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist; Glucocorticoid receptor antagonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 4 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| TUBA1A | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
| TUBA3E | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/112714 | Drugs and targets |
| TUBA4A | Tubulin | 4 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7277 | Drugs and targets |
1 to 10 of 141
See all 141 targetsTrials80
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00002597 | Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer | Phase 3 | 2,028 | 2017-06-06 | Prostate Cancer | FLUTAMIDE, GOSERELIN, LEUPROLIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00005044 | Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | Phase 3 | 1,579 | 2017-10-31 | Prostate Cancer | BICALUTAMIDE, FLUTAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00004124 | S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer | Phase 3 | 983 | 2018-09-04 | Prostate Cancer | BICALUTAMIDE, GOSERELIN, MITOXANTRONE, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT03686683 | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer | Phase 3 | 532 | 2024-10-08 | Adenocarcinoma of the Prostate | SIPULEUCEL-T | Its record names the disease | ClinicalTrials.gov |
| NCT00065442 | Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | Phase 3 | 512 | 2010-09-06 | Prostate Cancer | SIPULEUCEL-T | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03706365 | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | Phase 2/3 | 393 | 2025-03-06 | Prostate Cancer | ABEMACICLIB, ABIRATERONE ACETATE, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT00626431 | A Study of Leuprolide to Treat Prostate Cancer | Phase 3 | 310 | 2010-11-01 | Prostate Cancer | LEUPROLIDE ACETATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01666314 | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer | Phase 1/2 | 137 | 2018-03-20 | Prostate Cancer | ORTERONEL, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Phase 2 | 76 | 2021-04-19 | Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma, Soft Tissue Sarcoma, Ovarian Adenocarcinoma, Advanced Well-differentiated Neuroendocrine Tumors, Diffuse Large B Cell Lymphoma | IERAMILIMAB, SPARTALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00527124 | Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | Phase 2 | 57 | 2014-03-11 | Adenocarcinoma of the Prostate, Stage IV Prostate Cancer | CEDIRANIB, DOCETAXEL, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 80
See all 80 trialsComparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Neoadjuvant TAS 2 Months Before and During RT vs Radiation Therapy Alone: serious adverse events | 33 of 1,003 | 16 of 1,003 | 2,006 | NCT00002597 | Trial comparisons |
| TAS x 8 Weeks vs TAS x 28 Weeks: serious adverse events | 121 of 747 | 109 of 735 | 1,482 | NCT00005044 | Trial comparisons |
| Arm I: Bicalutamide + Goserelin vs Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin: deaths from any cause | 85 of 469 | 91 of 460 | 929 | NCT00004124 | Trial comparisons |
| Arm I: Bicalutamide + Goserelin vs Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin: serious adverse events | 3 of 469 | 11 of 460 | 929 | NCT00004124 | Trial comparisons |
| Treatment Group: Sipuleucel-T vs Control Arm: Active Surveillance: Efficacy of Sipuleucel-T Measured as the Percentage of Subjects Without Histological Reclassification (Gleason Group Upgrade). | 108 of 356 | 48 of 176 | 532 | NCT03686683 | Trial comparisons |
| Treatment Group: Sipuleucel-T vs Control Arm: Active Surveillance: deaths from any cause | 10 of 356 | 5 of 176 | 532 | NCT03686683 | Trial comparisons |
| Treatment Group: Sipuleucel-T vs Control Arm: Active Surveillance: serious adverse events | 74 of 345 | 22 of 176 | 521 | NCT03686683 | Trial comparisons |
| Sipuleucel-T vs APC-Placebo: serious adverse events | 82 of 338 | 40 of 168 | 506 | NCT00065442 | Trial comparisons |
| Abemaciclib vs Placebo: deaths from any cause | 81 of 206 | 72 of 187 | 393 | NCT03706365 | Trial comparisons |
| Abemaciclib vs Placebo: serious adverse events | 89 of 206 | 66 of 185 | 391 | NCT03706365 | Trial comparisons |
1 to 10 of 26
See all 26 comparisons in its trialsPapers from its trials46
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005082
GET https://conductscience.org/api/diseases/v1/MONDO_0005082/drugs?page=2